The involvement of a chemokine receptor antagonist CTCE-9908 and kynurenine metabolites in cancer development
- PMID: 35789495
- DOI: 10.1002/cbf.3731
The involvement of a chemokine receptor antagonist CTCE-9908 and kynurenine metabolites in cancer development
Abstract
Cancer is the second leading cause of mortality worldwide. Skin cancer is the most common cancer in South Africa with nearly 20,000 reported cases every year and 700 deaths. If diagnosed early, the 5-year survival rate is about 90%, however, when diagnosed late, the 5-year survival rate decreases to about 20%. Melanoma is a type of skin cancer with an estimated 5-year survival rate of approximately 90%. Neuroblastoma is a paediatric cancer with a low survival rate. Sixty percent of patients with metastatic disease do not survive 5 years after diagnosis. Despite recent advances in targeted therapies, there is a crucial need to identify reliable prognostic biomarkers which will be able to contribute to the development of more precision-based chemotherapeutic strategies to prevent tumour migration and metastasis. The compound, CTCE-9908 inhibits the binding of CXC chemokine ligand 12 (CXCL12) to the CXC chemokine receptor 4 (CXCR4) receptor leading to reduced metastasis. Kynurenine metabolites are derived tryptophan, which is an essential amino acid. Kynurenine metabolites inhibit T-cell proliferation resulting in cell growth arrest. For this reason, chemokines receptors represent potential targets for the treatment of cancer growth and metastasis. In this review paper, the role of the CXCL12/CXCR4 signalling pathway in the development of cancer is highlighted together with the current available treatments involving the CTCE-9908 compound in combination with microtubule inhibitors like paclitaxel and docetaxel.
Keywords: CTCE-9908; kynurenic acid; l-Kynurenine; melanoma; neuroblastoma; quinolinic acid.
© 2022 The Authors. Cell Biochemistry and Function published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
-
- Skin Cancer Foundation. Melanoma overview, a dangerous skin cancer; 2020. www.skincancer.org
-
- The Cancer Association of South Africa (CANSA). skin cancer leaflet; 2020. www.cansa.org.za
-
- Tod BM, Kellett PE, Singh E, Visser WI, Lombard CJ, Wright CY. The incidence of melanoma in South Africa: an exploratory analysis of national cancer registry data from 2005 to 2013 with a specific focus on melanoma in black Africans. S Afr Med J. 2019;109(4):246-253.
-
- Rebecca VW, Somasundaram R, Herlyn M. Pre-clinical modeling of cutaneous melanoma. Nat Commun. 2020;11(1):2858. doi:10.1038/s41467-020-15546-9
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
